Programmed death-ligand 1 immunohistochemistry in lung cancer: In what state is this art?

Journal of Thoracic Oncology

Volumn 10, Issue 7, 2015, Pages 985-989

  Kerr, Keith M ^a   Tsao, Ming Sound ^b   Nicholson, Andrew G ^c   Yatabe, Yasushi ^d   Wistuba, Ignacio I ^e   Hirsch, Fred R ^f  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF COLORADO   (United States)

Author keywords

Biomarker assay; Immune check point inhibitors; Immunohistochemistry; PD 1; PD L1

Indexed keywords

BIOLOGICAL MARKER; EPITOPE; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; TUMOR MARKER;

CANCER INFILTRATION; CANCER PATIENT; CANCER PROGNOSIS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; NON SMALL CELL LUNG CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE; CHEMISTRY; IMMUNOLOGY; LUNG TUMOR; PATHOLOGY;

ANTIGENS, CD274; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS;

EID: 84942867600     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000526     Document Type: Review

References (23)

1. Brahmer JR, Drake CG, Wollner I, Phase I study of single-Agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010 28 3167 3175
2. Topalian SL, Hodi FS, Brahmer JR, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012 366 2443 2454
3. Sznol M, Chen L., Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 19 1021 1034
4. Brahmer JR., Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol 2013 31 1021 1028
5. Vogelstein B, Papadopolous N, Velculescu VE, Cancer genomic landscapes. Science 2013 339 1546 1558
6. Lawrence MS, Stojanov P, Polak Paz, Mutational heterogeneity in cancer and the search for new cancer genes. Nature 2013 499 214 218
7. Gettinger S, Shepherd FA, Antonia SJ, First-line nivolumab (Anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced non-small cell lung cancer (NSCLC): safety, efficacy, and correlation of outcomes with PD-L1 status. J Clin Oncol 2014 32 suppl; abstr 8024 5s
8. Rizvi NA, Shepherd FA, Antonio SJ, First-line monotherapy with nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in advanced non-small cell lung cancer (NSCLC): safety, efficacy, and correlation of outcomes with PD-L1 status. Int J Rad Oncol 2014 90 Suppl 2014 s31 (165)
9. Brahmer JR, Horn L, Gandhi L, Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer (NSCLC); survival and clinical activity by subgroup analysis. J Clin Oncol 2014 32 suppl; abstr 8112 5s
10. Gettinger S, Horn L, Gandhi L, Long-Term survival, clinical activity and safety of nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Int J Rad Oncol 2014 90 170 Suppl 2014 s34
11. Antonia SJ, Gettinger S, Chow LQ, Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in First-Line Non-Small Cell Lung Cancer (NSCLC): Interim Phase 1 Results. J Clin Oncol 2014 32 suppl; abstr 8023 5s
12. Ramalingham SS, Mazieres J, Planchard D, Phase II study of nivolumab (anti-PD-1) in patients with advanced, refractory squamous non-small cell lung cancer (LB2). Int J Rad Oncol 2014 90 Suppl 2014) 1266 1267
13. Taube JM, Klein A, Brahmer JR, Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Can Res 2014 20 5064 5074
14. Garon EB, Gandhi L, Rizvi N, Antitumor activity of pembrolizumab (Pembro; MK-3475) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients with advanced NSCLC. Ann Oncol 2014 25 suppl 4 1 41
15. Garon EB, Leighl NB, Rizvi NA, Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol 2014 32 suppl; abstr 8020 5s
16. Powderly JD, Koeppen H, Hodi S, Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study. J Clin Oncol 2013 31 suppl; abstr 3001
17. Soria JC, Cruz C, Bahleda R, Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). European J Cancer 2013 49 (Supplement 2, Abstract 3408)
18. Herbst RS, Soria JC, Kowanetz M, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014 515 563 567
19. Segal NH, Antonia SJ, Brahmer JR, Preliminary data from a multi-Arm expansion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol 2014 32 suppl; abstr 3002 5s
20. Brahmer JR, Rizvi NA, Lutzky J, Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. J Clin Oncol 2014 32 suppl; abstr 8021 5s
21. Bussolati G, Leonardo E., Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J Clin Pathol 2008 61 1184 1192
22. Yang CY, Lin MW, Chang YL, Wu CT, Yang PC., Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 2014 50 1361 1369
23. Velcheti V, Schalper KA, Carvajal DE, Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014 94 107 116